Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nichi-Iko to Join Forces with Kyowa in Generic Production, Eyeing Reorganization
July 24, 2024
- Moderna, University of Tokyo Link Arms on mRNA Technology
July 24, 2024
- Kobayashi Pharma Replaces Management after Beni-Koji Scandal
July 24, 2024
- Axcelead-Teijin JV Anticipates Synergies in Common Disease Areas, Pipelines
July 23, 2024
- Astellas, Osaka University Join Hands in Cell Therapy Research
July 23, 2024
- MSD Seeks Japan Nod for RCC Med Belzutifan
July 23, 2024
- Mochida Files Pediatric Dosage of UC Drug Lialda in Japan
July 23, 2024
- Chugai to Offload Hyperammonemia Drug to Maruishi
July 23, 2024
- Terumo to End Sale of HeartSheet after Panel’s Thumbs-Down
July 22, 2024
- Deciphera’s TGCT Drug Accepted for Review in Europe: Ono
July 22, 2024
- FDA Clears IND for Japan JV’s Peptide-Based COVID Therapy
July 19, 2024
- Opdivo Extends Label for Frontline Bladder Cancer in South Korea
July 19, 2024
- Renalys Raises 6 Billion Yen in Series A Financing to Push IgA Med
July 18, 2024
- BMS Files Hypertrophic Cardiomyopathy Drug in Japan
July 18, 2024
- Eisai Hands Over Fosravuconazole Rights in Asia/Oceania to Sato
July 17, 2024
- Kissei Clears Primary Goal for Linzagolix in Japan PIII
July 17, 2024
- Sumitomo Nabs FDA’s Fast-Track Tag for Cancer Med DSP-5336
July 17, 2024
- Insmed Set to Double Japan Staff by 2025-End as It Gears Up for Brensocatib Debut
July 17, 2024
- Senju/Mochida's Dry Eye Med Scores PIII Primary Endpoint
July 17, 2024
- LTL, Cheplapharm Envision Heightened Opportunities for LLP Takeovers under Elective Care Scheme
July 16, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…